Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Protalix raises $60 million note deal

Protalix BioTherapeutics Inc. (NYSE-M:PLX; Tel Aviv:PLX) raised $60 million in a note

Read the full 125 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE